The Role of Factors of Angiogenesis in Patients with Neuroendocrine Tumors of Gastrointestinal Tract and Pancreass
- 1 д.м.н., доцент, кафедра онкологии, ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России
- 2 д.б.н., вед. науч. сотрудник, лаборатория клинической биохимии, РОНЦ им. Н.Н.Блохина РАМН
- 3 д.м.н., вед. науч. сотрудник, хирургическое отделение диагностики опухолей, РОНЦ им. Н.Н.Блохина РАМН
- 4,5 аспирант, кафедра онкологии, ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России
Keywords:
vascular endothelial growth factor (VEGF)endostatintumor necrosis factor (TNF-βneuroendocrine tumor
Abstract
We compared serum vascular endothelial growth factor (VEGF), endostatin and tumor necrosis factor (TNF-β) levels in 20 patients with neuroendocrine tumors and 25 practically normal donors (control group). Mean serum VEGF, endostatin and TNF-β concentrations in neuroendocrine tumors cases were not significantly different from control. There was no relationship between VEGF, endostatin and TNF-β levels and patients, gender and age. Patients with malignant neuroendocrine tumors presented relationship between serum endostatin and TNF-β levels and tumors size. Cases with benign neuroendocrine tumors demonstrated a significant positive correlation between serum VEGF and endostatin levels, but an inverse relationship between serum VEGF and TNF-β levels. High levels of serum endostatin and (>100 ng/ml) low levels TNF-β (<30 pg/ml) may predict worse disease free survival. Longer follow-up is needed for assessment of effect on survival.
How to cite
Поликарпова С.Б., Любимова Н.В., Ожерельев А.С., Боровская Н.И., Кокалишвили А.Т. Роль факторов ангиогенеза у больных нейроэндокринными опухолями органов брюшной полости // Вопросы биологической, медицинской и фармацевтической химии. 2011. № 12. С. 50–54.
References
- Folkman J. Tumor angiogenesis. The molecular Basis of Cancer / eds: J. Mendelsohn, P.M. Howley, M.A. Israel, L.A. Liotta. Philadelphia: Saunders. 1995. P. 206-232.
- Dhanabal M., Volk R., Ramchandran R. Endostatin induces endothelial cell apoptosis // J. Biol. Chem. 1999. V. 274. P. 11721-11726.
- Aggarwal B.B. Tumor necrosis factors - TNF-α and TNF-β: their structure and pleiotropicbiological effects // Drugs Future. 1987. V. 12. P. 891-898.
- Paul N.L., Ruddle N.H. Lymphotoxin // Ann. Rev. Immunol. 1988. V. 6. P. 407-438.
- Bachelot T., Ratel D., Menetrier-Caux C., Wion D., Blay J.Y., Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome // Br. J. Cancer. 2006. V. 94. № 7. P. 1066-70.
- Dudek A.Z., Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival // Cancer Invest. 2005. V. 23. № 3. P. 193-200.
- Kolomecki K., Stepien H., Narebski J. M. Vascular endothelial growth factor and basicfibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumors // Cytobios. 2000. V. 101. № 396. P. 55-64.
- Swidzinska E., Ossolinska M., Naumnik W., Trojan S., Chyczewska E. Serum endostatin levels in patients with lung carcinoma // Rocz. Akad. Med. Bialymst. 2005. V. 50. P. 197-200.
- Wrobel T., Mazur G., Kapelko K., Kuliczkowski K. Endostatin serum level in acute myeloidleukemia // Neoplasma. 2005. V. 52. № 2. P. 182-184.
- Gruszka A., Kunert-Radek J., Pawlikowski M., Stepien H. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas // Pituitary. 2005. V. 8. № 2. P. 163-168.